Moreover, isorhamnetin can inhibit cardiac hypertrophy and fibrosis by blocking the activation of the phosphatidylinositol 3-kinase-AKT (protein kinase B) signaling pathway. Here, AKT1 is linked to cardiac hypertrophy.